Schizophrenia has been associated with altered immunity and reduced occurrence of autoimmune diseases and malignancies. A few studies in schizophrenic patients have assessed natural killer cell activity (NKA), but no consistent findings have emerged. However, NKA was assessed using standard procedures and in the absence of autologous serum and the various cytokines that modulate NKA and appear to be abnormal in schizophrenic patients. In the current study, therefore, the number of NK cells and the activity of the individual NK cell were assessed in whole blood shortly after blood withdrawal, in both the presence and the absence of autologous serum. Twenty-nine schizophrenic patients (11 nonmedicated), 8 nonschizophrenic control patients (bipolar and personality disorders), and 31 age-matched healthy controls were studied. Schizophrenic patients showed higher NKA per NK cell than controls and nonschizophrenic patients. This difference remained significant even when the nonmedicated schizophrenics, who showed the highest levels of NKA, were excluded. However, the increase in NKA was more pronounced in the presence of serum and was reduced to an insignificant level when serum was removed from the same samples. In both schizophrenic patients and controls, smokers and women showed lower NKA. Numbers of NK cells did not differ among groups, although medication affected blood concentration of other leukocytes. These findings indicate that the effects of serum factors, psychiatric medication, gender, and smoking should be considered when assessing NKA in schizophrenic patients. The observed higher NKA may help explain the surprising reports of low incidence of lung cancer and other malignancies in schizophrenic patients, despite their higher rate of smoking.
INTRODUCTION
The etiology and pathophysiology of schizophrenia are usually studied in relation to central nervous system abnormalities. However, both the underlying causes and the manifestation of the disease have been suggested to include various immune abnormalities (for review see Muller, 1995) . Several researchers have suggested that abnormal levels or activity of lymphocytes, cytokines, or cytokine receptors, at adulthood or during the perinatal period, may play a role in the etiology of schizophrenia (Fudenberg, Whitten, Merler, & Farmati, 1983; Ganguli, Rabin, & Belle, 1989; Gilmore & Jarskog, 1997; Knight, 1984; Noy, Achiron, & Laor, 1994; Pandey, Gupta, & Chaturvedi, 1981; Smith, 1991a) . Furthermore, various types of cancer (Baldwin, 1979; Gulbinat, Dupont, Jablensky, Jensen, Marsella, Nakane, & Sartorius, 1992) and autoimmune diseases, such as rheumatoid arthritis (Eaton, Hayward, & Ram, 1992) , are less prevalent in schizophrenic patients. These epidemiological findings may be related to the various aspects of immune function reported to be abnormal in patients with schizophrenia. These immune abnormalities include (a) alteration in the levels of IL-1, IL-2, and IL-6 and in the levels of the soluble cytokine receptors IL-2R, s-IL-2R, and IL-6R in the plasma (Barak, Barak, Levine, Nisman, & Roisman, 1995; Ganguli, Brar, Chengappa, DeLeo, Yang, Shurin, & Rabin, 1995; Ganguli et al., 1989; Katila, Hurme, Wahlbeck, Appelberg, & Rimon, 1994; Maes, Bosmans, Calabrese, Smith, & Meltzer, 1995; Sirota, Schild, Elizur, Djaldetti, & Fishman, 1995; Smith, 1991b) and in the cerebrospinal fluid (Barak et al., 1995; Katila et al., 1994; Licinio, Seibyl, Altemus, Charney, & Krystal, 1993; Yang, Chengappa, Shurin, Brar, Rabin, Gubbi, & Ganguli, 1994) and (b) alteration in the concentration or activity of T cells and other lymphocyte subtypes (Bessler, Eviatar, Meshulam, Tyano, Djaldetti, & Sirota, 1987; Coffey, Sullivan, & Rice, 1983; DeLisi, Goodman, Neckers, & Wyatt, 1982; Muller, Ackenheil, Hofschuster, Mempel, & Eckstein, 1991; Sasaki, Nanko, Fukuda, Kawate, Kunugi, & Kazamatsuri, 1994) .
Natural killer (NK) cells are predominantly large granular lymphocytes (LGL) which express CD16 and/or CD56 surface antigens and comprise 10 to 15% of human peripheral blood lymphocytes (Robertson & Ritz, 1990) . NK cells are considered key players in the initial defense against virally infected or malignant cells (Barlozzari, Reynolds, & Herberman, 1983; Herberman & Ortaldo, 1981) . Studies in humans have found a positive correlation between levels of NK activity (NKA) and resistance to malignancy (Brittenden, Heys, Ross, & Eremin, 1996; Roder, Haliotis, Klein, Korec, Jett, Ortaldo, Heberman, Katz, & Fauci, 1980; Sullivan, Byron, Brewster, & Purtilo, 1980; Vujanovic, Basse, Herberman, & Whiteside, 1996) , and this relationship has been causally demonstrated using animal models (Barlozzari et al., 1983; Ben-Eliyahu & Page, 1992; Brittenden et al., 1996; Gorelik, Wiltrout, Okumura, Habu, & Herberman, 1982; Hanna & Burton, 1981; Shakhar & Ben-Eliyahu, 1998 ).
Studies of NKA in patients with schizophrenia show little agreement in their results. While a few studies have reported lower NKA (Abdeljaber, Nair, Schork, & Schwartz, 1994; Urch, Muller, Aschauer, Resch, & Zielinski, 1988) , and two studies have reported increased NKA (Ghosh & Chattopadhyay, 1993; Wang, 1987) , the majority have found no significant difference between schizophrenic patients and controls (Caldwell, Irwin, & Lohr, 1991; DeLisi, Ortaldo, Maluish, & Wyatt, 1983; Licinio et al., 1993; Schindler, Leroux, Beck, Moises, & Kirchner, 1986) . These inconsistencies may reflect procedural differences in the assessment of NKA or differences in the characteristics of the patients sampled. Additionally, various factors that are known to affect NKA are associated with schizophrenia and may have had confounding effects. For example, although smoking has been suggested to reduce NKA (Hughes, Haslam, Townsend, & Turner-Warwick, 1985; Phillips, Marshall, Brown, & Thompson, 1985) and is three times more prevalent in schizophrenic patients (Masterson & O'Shea, 1984) , its impact has not been addressed in studies assessing NKA in schizophrenia.
Given that schizophrenic patients are characterized by abnormal levels of cytokines that are known to modulate NKA (e.g., IL-1 and IL-2) (Henney, Kuribayashi, Kern, & Gillis, 1981; Lichtman, Chin, Schmidt, & Abbas, 1988) , the suggested lower incidence of cancer in schizophrenic patients, and the role of NK cells in controlling tumor development, it seems possible that schizophrenic patients are characterized by altered levels of NKA. Therefore, we sought to assess NKA using procedures that would increase the likelihood of detecting the influences of in vivo factors, such as serum cytokines and hormones. To this end we employed two different procedures for assessing NKA. The first-the whole blood assay-uses complete blood, with serum and all cell types present. Co-incubation with tumor cells is conducted shortly after blood sampling. This procedure would appear to preserve more of the characteristics of the in vivo milieu than standard NK assays, in which serum and several leukocyte subpopulations are removed. In the second procedure-the washed blood assay-serum is replaced with an artificial medium, as in standard procedures, but all cell subpopulations are maintained. These two procedures were previously used and validated in humans, and were shown to indicate cytotoxicity carried only by NK cells (Ottenhof, Morales, & Baines, 1981; Ree & Platts, 1983) .
Additionally, we aimed to systematically assess the effects of smoking and medication on NKA in schizophrenic patients. Thus, the current study assessed both the number and activity of NK cells in medicated, nonmedicated, smoking, and nonsmoking patients with schizophrenia, using the above two procedures for assessing NKA.
METHODS

Subjects
Blood samples were obtained from 68 subjects. Table 1 summarizes the subjects' characteristics. Informed consent was obtained from all 68 subjects. Schizophrenic and nonschizophrenic patients. Twenty-nine schizophrenic and 8 nonschizophrenic (4 bipolar disorder and 4 personality disorders) patients were recruited. All patients were hospitalized at Abarbanel Mental Health Center, Bat Yam, Israel, at the time of blood sampling. The patients were diagnosed according to DSM-IV criteria (American Psychiatric Association, 1994 ) and the Structural Clinical Interview for DS-R-Patients Edition (SCID-P) (Spizer, 1989) . A detailed history was obtained from each patient, and a complete physical examination was performed. In addition, all subjects filled out a questionnaire regarding drug use, smoking habits, physical activity, weight and height, recent incidents of infectious disease, illness, and traumatic events. Eleven schizophrenic patients were nonmedicated and were admitted to the hospital between 1 and 3 days before blood was taken and were given medication only afterward. These patients had not been on medication for at least 8 weeks prior to the study. Subjects participating in the study had no acute or chronic physical illnesses (e.g., autoimmune disease and/or infection) and had not used any drugs (other than psychiatric medication) known to affect the immune system for at least 2 weeks prior to blood sampling.
Healthy controls. Thirty-one healthy control subjects volunteered or were paid to participate in the study. The participants filled out a questionnaire identical to the one completed by patients. Subjects who had used any drug 2 weeks prior to their test were excluded.
Blood Collection
Blood was collected into heparinized (20 U/ml blood) vacutainers between 8:00 and 10:00 AM. Overall, 10 different assays were conducted, each using a designated sample of patients and controls. The NKA assay and the FACS analysis were performed on the freshly drawn blood samples within 2-4 h of blood withdrawal. The blood samples were randomly numbered and were uniformly treated by the laboratory staff, who were unaware of the source of each sample.
Radiolabeling of K562 Target Cells
The standard NK-sensitive K562 tumor line (Lozzio & Lozzio, 1979) was used as the target for the NK cytotoxicity assay. The cells were grown at 37°C in 5% CO 2 in complete medium (CM) (RPMI 1640 medium, (Biological Industries, Beit Haemek, Israel) supplemented with 10% heat-inactivated fetal calf serum (FCS), 50 µg/ml gentamycin, 2 mM L-glutamine, 0.1 mM nonessential amino acids, and 1 mM sodium pyruvate). For radiolabeling, cells were incubated with 51 Cr (1 h of incubation with 200 µCi, 400 µl FCS, and 300 µl CM per 4 ϫ 10 7 cells). Following incubation, cells were washed twice with CM (300g, for 10 min) and adjusted to a concentration of 2 ϫ 10 6 /ml. Serial threefold dilutions were performed to achieve 5 target cell concentrations ranging from 2 ϫ 10 6 to 25,000 (2/81 ϫ 10 6 ) K562 cells/ml. The higher four concentrations were used for the whole blood assay and the lower four concentrations were used for the washed blood assay.
NK Cytotoxicity Assays
Two different procedures were used to assess NKA, the whole blood assay, which preserves the subject's serum, and the washed blood assay, which replaces it with an artificial medium. Both procedures were performed in parallel on aliquots of blood from each subject. These two procedures differ from standard procedures in that they assess anti-tumor cytotoxicity following minimal manipulation of the blood (e.g., no exclusions of cell subpopulations or adhesion sorting) and are conducted very shortly after blood withdrawal. The two procedures were previously validated and used in humans and were shown to reflect the cytotoxicity carried by NK cells alone (Ottenhof et al., 1981; Ree & Platts, 1983) . The four different concentrations of target cells (K562) used in each method were determined in pilot studies and set to achieve optimal levels of killing (increasing towards a plateau) in each method.
Whole blood assay. For each of the four target cell concentrations used, duplicates of 200 µl of the freshly drawn blood were placed into two wells of a microtiter plate. Fifty microliters of the 51 Cr-labeled K562 tumor cells in CM was then added on top of the blood. A concentration of 2ϫ10 6 K562/ml was used for the lowest E:T ratio and sequentially divided by three for higher E:T ratios. The small volume of target cell suspension was chosen to minimize the dilution of the plasma. To determine spontaneous and maximal 51 Cr releases, blood was substituted with 200 µl of CM or HCl (4%), respectively. Plates were centrifuged at 500g for 10 min to create a buffy coat layer of leukocytes and target cells on top of the red blood cells and were then incubated for 4 h in 5% CO 2 at 37°C. Following incubation, plates were centrifuged again and aliquots of 100 µl of the supernatant were recovered from each well for assessment of radioactivity in a γ counter.
Washed blood assay. Exactly 1 ml of blood was washed once with phosphatebuffered saline (PBS) (four times the blood volume) and twice with CM (three times the blood volume, 15% FCS). For each wash, the diluted blood was centrifuged at 400g for 10 min, and the supernatant was removed to restore the original blood volume. This procedure resulted in the replacement of the serum with CM. For each of the four target cell concentrations used, duplicates of 100 µl of the washed blood were placed in two wells of a microtiter plate, and 150 µl of the 51 Cr-labeled K562 tumor cells in CM was then added on top of the blood. A concentration of 6 ϫ 10 5 K562/ml was used for the lowest E:T ratio and sequentially divided by three for higher E:T ratios. From this stage onward, the washed blood procedure was the same as the whole blood procedure.
Fluorescence-Activated Cell Sorter (FACS) Analysis
In order to identify and count the three NK subpopulations (CD3
, three-color direct immunofluorescence analysis of surface markers was performed using mAbs for CD3 (conjugated with FITC; Coulter), CD16 [conjugated with R-phycoerythrin cyanine 5 (PE-Cy5); Immunotech], CD56 [conjugated with phycoerythrin (PE); Coulter], and their respective nonspecific mAbs. For a detailed description of the flow cytometry procedure (see Shakhar & Ben-Eliyahu, 1998) . Ottenhof et al. (1981) analyzed the specificity of NKA in the whole blood procedure and reported that granulocytes, monocytes, and any plasma factors did not show cytolytic activity in this assay. It was also reported that red blood cells did not influence natural cytotoxicity. The only cell subpopulation which displayed cytotoxic activity against the K562 tumor cells was FcR ϩ lymphocytes (Ree & Platts, 1983) . Other blood factors did, however, contribute to the level of cytotoxicity, but only through their interaction with the effector cells, rather than directly with the target cells (K562) (Ottenhof et al., 1981) .
Identification of the Effector Cells Participating in K562 Cytotoxicity
The antigens considered as NK cell markers for clinical and basic research purposes are CD56 (NKH-1, Leu-19) and CD16 (Fcγ R III). The CD56 is expressed by all human peripheral blood cells capable of non-MHC-restricted cytotoxicity (Robertson & Ritz, 1990 (Lanier, Le, Civin, Loken, & Phillips, 1986) . However, Lanier et al. (1986) found that the level of K562 cytotoxicity of the CD3 Ϫ populations was markedly higher than that of the ''non-MHC-restricted T cells.'' These findings indicate that the main cell subpopulation responsible for the lysis of K562 in vitro is CD3 Ϫ
CD56
ϩ regardless of CD16 expression. Therefore, the E:T ratios were established individually for each subject according to his/her actual number of CD3 Ϫ CD56 ϩ cells/ml of blood. This criterion is common to most human studies assessing antibody-independent NKA per cell (Robertson & Ritz, 1990) .
Data Analysis
Natural killer lysis. The percentage of specific lysis for each target cell concentration was calculated by the standard formula for the whole and washed blood procedures (Ottenhof et al., 1981) . Since the 51 Cr released by the labeled target cells is found only in the supernatant above the red blood cells (Ottenhof et al., 1981) , the total volume is corrected by subtracting the red blood cell volume [% hematocrit (Hct) ϫ blood volume (V b )] from the total volume (V t ).
where cpm is counts per minute, SR is 51
Cr spontaneous release per minute, MR is 51 Cr maximum release per minute, b is background count per minute, V t is total volume in well (blood ϩ target cell), V b is total blood volume in the well, and Hct is percentage hematocrit. In order to determine the level of cytotoxicity per NK cell, the effector to target (E:T) ratio was calculated for each subject individually according to his/her number of CD3 Ϫ CD56ϩ (effector cells) per milliliter of blood and the known number of K562 cells (target cells) in each well, using the regression exponential fit method (Pollock, Zimmerman, Fuchshuber, & Lotzova, 1990) .
Number of NK Cells. A Fluorescence-Activated Cell Sorter (Becton-Dickinson) was used to identify and count the different leukocyte subpopulations. The percentage of leukocytes, lymphocytes, granulocytes, NK cell subpopulations (CD3
, and CD56 ϩ in the total counted events were assessed using the WinMDI 2.3 software -1996 .
To calculate the number of cells/ml of blood (CS/ml) of each cell subpopulation, a fixed amount of 3 ϫ 10 5 polystyrene microspheres/ml of blood was added to each sample (1.5 ϫ 10 4 /50 µl blood), and the following formula was used:
Number of cell subpopulation events Number of beads events ϫ No. of beads/ml ϭ CS/ml.
Statistical Analysis
NKA. All the statistical analyses of NKA were conducted using repeated-measures ANOVAs with the four E:T ratios as a within-subject factor. When ANOVA yielded significant differences, posthoc Games/Howell analysis was used to compare specific groups. This method was chosen because it allows comparisons between groups of unequal numbers of subjects. Alpha was set at 0.05 in all analyses. In the first analysis, the three groups (schizophrenic patients, nonschizophrenic patients, and healthy controls) were compared. Given the small number of nonschizophrenic patients, this group was excluded from analyses that required subdivision of the groups. These higher level analyses employed two-and three-way ANOVAs, with smoking, medication, and sex as additional factors.
To assess the effect of age on NK activity, linear and second-order polynomial regression analyses were conducted on each of the four E:T ratios.
Leukocyte subtypes. Changes in leukocyte numbers were analyzed using a factorial ANOVA, with sex and group as independent variables. In addition, two separate analyses of the effects of medication and smoking and their interaction with schizophrenia were performed.
RESULTS
Whole Blood NKA
Levels of NKA of 29 schizophrenic patients, 8 nonschizophrenic patients, and 31 control subjects were tested in the whole blood assay.
The effects of schizophrenia. Schizophrenic patients exhibited higher NKA than controls and nonschizophrenic patients. One-way ANOVA indicated significant differences among these three groups (F(2,65) ϭ 4.07, p ϭ .021), and posthoc Games/ Howell analysis indicated that schizophrenic patients were significantly higher than the controls and the nonschizophrenic patients (Fig. 1) . Nonschizophrenic patients exhibited levels of NKA very similar to control levels.
As the group of nonschizophrenic patients was too small to be subdivided for higher level ANOVA, it was excluded from further analysis.
The effect of smoking. Since smokers were more numerous among schizophrenic patients, and smoking has been reported by some studies to reduce NKA, we included smoking as a factor in the analysis. Figure 2 shows that smoking tended to reduce NKA, especially in schizophrenic patients. Although the effect of smoking did not reach statistical significance (F(1,56) ϭ 2.7, p ϭ .1), the effect of schizophrenia (F(1,56) ϭ 8.1, p ϭ .006) became more significant when smoking was taken into account (p ϭ .006 vs. .01).
The effect of sex. In both schizophrenic patients and controls, males exhibited higher NKA than females. Three-way repeated-measure ANOVA, with schizophrenia, sex, and smoking as independent factors, revealed significant main effects of schizophrenia (F(1,52) ϭ 6.138, p ϭ .016) and of sex (F(1,52) ϭ 4.84, p ϭ .032), but no significant effect of smoking or any interactions. Figure 3 depicts the effects of sex across all other factors. The effect of psychiatric medication. Of the 29 schizophrenic patients, 11 were nonmedicated. These patients, hospitalized 1-3 days before blood sampling, showed on average higher levels of NKA than the medicated patients (Fig. 4) . To determine whether psychiatric medication affected levels of NKA, two-way repeated-measure ANOVAs were conducted on all three groups, with smoking as a second factor, followed by specific contrasts. Whereas ANOVA indicated significant group differences [F(2,54) ϭ 4.8, p ϭ .011], posthoc analysis indicated significant differences between the control group and each of the schizophrenic groups, but not between the medicated and nonmedicated schizophrenic groups. The effect of smoking was not significant.
No linear effect of age. We examined the effect of age on NKA using linear and second-order polynomial regression. No significant effect of age was revealed in any of the effector to target ratios. However, there was a tendency toward an inverted Both subgroups of schizophrenic patients were significantly higher than the control group, but no significant differences were found between these groups using posthoc analysis. U-shaped relation between age and NKA, peaking at the mid forties. Since this trend appeared in patients and controls alike, and since the groups were age-matched, the potential effects of age should not have influenced our results.
No direct effect of serum on target cells. It is important to verify that changes in NKA detected using the whole blood assay are caused by changes in cytotoxicity of effector cells, rather than by serum factors capable of killing tumor cells directly. Therefore, we also assessed the possible cytotoxicity of the subjects' serum in the absence of leukocytes. As previously reported (Ottenhof et al., 1981; Ree & Platts, 1983) , no cytotoxicity was found: the levels of spontaneous release of 51 Cr in the presence of serum from control or schizophrenic patients were similar to the levels of spontaneous release when serum was substituted by complete medium. Thus, the elevated NKA observed in schizophrenic patients is attributable to a higher activity of NK cells and not to the killing of tumor cells by serum factors alone.
Washed Blood
Levels of NKA of 27 schizophrenic patients and 31 control subjects were measured using the washed blood assay (due to technical problems the data of 2 schizophrenic patients were unusable).
The analysis of the effects of schizophrenia, medication, sex, and smoking on NKA yielded a pattern of results similar to those in the whole blood analyses, but the effects were smaller and not significant. This lack of effects is not attributable to more variance in the washed blood assay or to technical problems. The assay yielded increasing levels of killing (ranging from 10 to 45% in the different E:T ratios, as seen in Fig. 5) , and the differences between duplicates were less than 5%.
Two observations, although not statistically significant, are noteworthy. Nonmedicated schizophrenic patients had higher NKA than controls, whereas medicated schizophrenic patients had NKA similar to that of controls (F(2,55) ϭ 2.3, p ϭ .1). Nonmedicated nonsmoking schizophrenic patients exhibited the highest NK activity in the washed blood assay, as was the case in the whole blood assay.
Leukocyte Subtypes
The number of leukocytes of different subtypes was available for 28 control subjects and 10 nonmedicated and 16 medicated schizophrenic patients.
The analysis of the effects of schizophrenia, sex, and smoking on the number of leukocytes, granulocytes, lymphocytes, NK cells (CD3
, and CD56 ϩ per milliliter of blood yielded no significant differences (Table 2) .
A significant effect of medication was, however, found in the number of leukocytes [F(2,52) ϭ 3.4, p Ͻ .05] and the number of lymphocytes [F(2,52) ϭ 3.6, p Ͻ .05] per milliliter of blood. Posthoc analysis showed that medicated schizophrenic patients had a significantly higher number of leukocytes and lymphocytes than nonmedicated schizophrenic patients. Additionally, nonmedicated schizophrenic patients showed a lower number of lymphocytes than controls.
DISCUSSION
Previous research has suggested that schizophrenic patients manifest abnormal immune functions. In the current study, schizophrenic patients showed higher NKA than healthy control subjects and nonschizophrenic patients (bipolar and personality disorders): half as many NK cells from schizophrenics patients were required to achieve similar levels of cytotoxicity compared to control levels. Nonmedicated schizophrenic patients demonstrated the highest NKA, whereas medicated schizophrenic patients displayed intermediate levels of NKA (significantly higher than controls and insignificantly lower than nonmedicated patients). In both schizophrenic and control groups, women displayed lower NKA than men, and smokers tended to exhibit reduced NKA. Importantly, the above findings were significant only in the whole blood assay, in which autologous serum and its factors were present during the assessment of NKA.
To the best of our knowledge, this study is the first to address the effects of preserving autologous serum when assessing NKA in schizophrenic patients. The rationale for using the whole blood procedure was based on reports of aberrations in the levels of serum IL-1, IL-2, and IL-6 (Barak et al., 1995; Ganguli et al., 1995 Ganguli et al., , 1989 Katila et al., 1994; Maes et al., 1995; Sirota et al., 1995; Smith, 1991b) and various other immune indices (Bessler et al., 1987; Coffey et al., 1983; DeLisi et al., 1982; Muller et al., 1991; Muller, Schlesinger, Hadjamu, Riedel, Schwarz, Ackenheil, Wank, & Gruber, 1998) , which may influence NKA in schizophrenic patients (e.g., higher number and activity of T cells (Lanier et al., 1986) ). Because it is reasonable to assume that in vivo levels of NKA are better reflected using a whole blood assay that preserves autologous serum and is conducted shortly after blood sampling, these findings also suggest that schizophorenic patients may have increased NK-mediated resistance against disease. Moreover, our findings indicate increased NKA per individual NK cell, with no evidence of alterations in NK cell numbers. Because only a small portion of NK cells is to be found in circulating blood, no direct conclusions could be drawn regarding NKA in other immune compartments. Nevertheless, the fact that the changes in NKA seem to be dependent upon soluble serum factors common to many immune compartments implies that NKA may be elevated in other compartments as well (e.g., lungs, lymph nodes, spleen, liver).
The current study indicated that, as has been previously reported in healthy subjects, the serum of schizophrenic patients does not lyse target cells directly. The whole blood assay has been shown to assess cytotoxicity carried out by NK cells, rather than other cell types or serum factors (Ottenhof et al., 1981; Ree & Platts, 1983) . However, in this assay such cells or factors may influence NK cytotoxicity either in vivo or in vitro. Thus, the whole blood assay cannot point to a specific factor underlying the increased NKA in schizophrenic patients. Given the intricacy of immune abnormalities in schizophrenic patients (Muller, 1995) , it seems premature to speculate as to the exact immunological mechanisms underlying the elevated levels of NKA.
The enhanced NKA in schizophrenic patients may be related to altered central dopaminergic activity. Several studies have reported a positive correlation between brain levels of dopamine (DA) and activity of NK cells. Bilateral lesions of the nigrostriatal system and the consequent reduction in the striatal DA levels have been shown to result in reduced NKA and enhanced tumor growth in mice (Basu, Dasgupta, & Chowdhury, 1995) . Conversely, chronic treatment with the DA agonist amphetamine increased NKA (Swerdlow, Hauger, Irwin, Koob, Britton, & Pulvirenti, 1991) . Finally, parkinsonian patients, who suffer from reduced central dopaminergic levels, have been reported to exhibit reduced NKA (Bokor, Farago, Garam, Malatinszky, & Schnabel, 1993) . Although circumstantial, these findings may imply that the observed higher NKA in schizophrenic patients is related to increased dopaminergic activity in this population. This preliminary hypothesis could be tested in schizophrenic patients with parkinsonian side effects, schizophrenic patients that are in full remission, and patients before and after treatment with various dopaminergic drugs. The current study provides preliminary indications that psychiatric medication may reduce the difference in NKA between schizophrenic patients and controls. This suggestion is consistent with the findings that both atypical and typical psychiatric medication normalize the abnormally high levels of IL-6 and soluble IL-6 receptor (Maes et al., 1995) , although other studies have reported smaller effects of medications on other immune indices or no effects at all (e.g., T cells mitogen response) (Rapaport, McAllister, Kirch, & Pickar, 1991) .
The observed higher NKA in schizophrenic patients may, to some degree, underlie the puzzling findings that, although more than 80% of schizophrenic patients are heavy smokers (de Leon, 1996) , there is no evidence for an increased rate of lung cancer in this population. On the contrary, several epidemiological studies have found a reduced prevalence of lung cancer and other types of cancer among schizophrenic patients (Craig & Lin, 1981; Gulbinat et al., 1992; Katz, Kunofsky, Patton, & Allaway, 1967; Mortensen & Juel, 1993; Rice, 1979) . In order to suggest that NK cells play a role in this phenomenon two pieces of evidence must be presented: (a) elevated NKA in schizophrenic patients and (b) a role for NK cells in controlling tumor development in humans. The current study showed that schizophrenic patients manifest higher levels of NKA than controls and that although smoking reduces NKA, smoking schizophrenic patients display higher levels of NKA than nonsmoking controls. This latter difference, however, did not reach statistical significance. As to the role of NK cells in controlling tumor development, animal studies have provided direct evidence, especially in respect to metastatic processes (Barlozzari, Leonhardt, Wiltrout, Herberman, & Reynolds, 1985; Ben-Eliyahu & Page, 1992; Gorelik, Segal, & Feldman, 1978; Shakhar & Ben-Eliyahu, 1998; Vujanovic, Herberman, & Hiserodt, 1988) . Studies in humans have found a positive correlation between NKA and resistance to malignancy (Brittenden et al., 1996) . For example, patients displaying lower levels of NKA [e.g., Chediak-Higashi syndrome (Roder et al., 1980) , X-linked lymphoproliferative syndrome (Sullivan et al., 1980) , and patients with major depression (Stein, Miller, & Trestman, 1991) ] have also been reported to show higher rates of cancer. Moreover, higher levels of NKA at the time of tumor removal have been associated with a better prognosis following excision of breast (Levy, Herberman, Maluish, Schlien, & Lippman, 1985) , head, and neck tumors (Schantz, Brown, Lira, Taylor, & Beddingfield, 1987) .
As shown earlier in normal subjects (Hughes et al., 1985; Phillips et al., 1985) , smoking reduced NKA in schizophrenic patients, and antipsychotic medication had similar effects. These factors may explain some of the inconsistencies in the literature: Smoking is approximately three times more prevalent in schizophrenic patients than in the general population (de Leon, 1996) , but previous studies in shizophrenic patients have failed to report whether a matched proportion of smokers was included in the control group, nor have they included smoking as a factor in the statistical analysis. Likewise, the effect of medication was not always considered.
Given that at least three factors shown to affect NKA differed between the schizophrenic subjects and the age-matched controls (i.e., smoking, gender, and medication), the current sample size is insufficient to determine to what degree each factor, if not controlled for, would attenuate or reverse the effect of schizophrenia. A larger sample could also suggest mechanisms underlying increased NKA in schizophrenic patients by correlating cytotoxicity with specific levels of cytokines. Nevertheless, it is noteworthy that although most schizophrenic subjects smoked more than controls and were medicated, their overall levels of NKA were still markedly higher than those of the control subjects.
In conclusion, our findings suggest that abnormally high levels of NKA may be a characteristic of schizophrenia. Moreover, this study demonstrates the importance of assessing NKA in the presence of serum factors, as well as the need to consider the effects of psychiatric medication and smoking when studying NKA in schizophrenic patients.
